Titan Biotech Q3 Profit Surges 107% YoY on Strong Revenue Growth

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Titan Biotech Q3 Profit Surges 107% YoY on Strong Revenue Growth
Overview

Titan Biotech Limited reported a stellar third quarter for FY26, with standalone net profit soaring 107.0% year-on-year to ₹786.82 Lakhs. Revenue from operations climbed 55.6% to ₹5,650.57 Lakhs, driven by strong market demand. For the nine-month period, standalone PAT rose 44.0% YoY to ₹2,089.15 Lakhs, with EPS at ₹25.28. Consolidated figures also showed robust year-on-year growth across key metrics.

📉 The Financial Deep Dive

Titan Biotech Limited has delivered an exceptionally strong performance for the third quarter and nine months ended December 31, 2025, showcasing significant year-on-year (YoY) expansion across its standalone and consolidated operations.

The Numbers:

  • Standalone Q3 FY26: Revenue from operations surged by a remarkable 55.6% YoY to ₹5,650.57 Lakhs. Profit Before Tax (PBT) saw an even steeper increase of 107.0% YoY, reaching ₹1,056.21 Lakhs. Consequently, Profit After Tax (PAT) grew by 107.0% YoY to ₹786.82 Lakhs. Basic Earnings Per Share (EPS) stood at ₹9.52, a substantial jump from ₹4.60 in Q3 FY25.
  • Standalone 9M FY26: For the nine-month period, revenue grew 29.7% YoY to ₹15,735.68 Lakhs. PBT and PAT both increased by 44.0% YoY, reaching ₹2,789.28 Lakhs and ₹2,089.15 Lakhs, respectively. The nine-month basic EPS was ₹25.28, up from ₹17.55.
  • Consolidated Q3 FY26: Consolidated revenue rose 46.0% YoY to ₹5,550.57 Lakhs. Consolidated PBT grew 105.2% YoY to ₹1,052.86 Lakhs, with PAT increasing 94.3% YoY to ₹852.86 Lakhs.
  • Consolidated 9M FY26: Consolidated revenue increased 25.4% YoY to ₹15,606.06 Lakhs. PBT and PAT also saw strong growth, with PAT rising 32.5% YoY to ₹2,315.61 Lakhs.

The Quality & Tax Impact:

The company reported no exceptional items, indicating that the substantial profit growth is driven by core operational performance. A key point noted is the company's election to exercise the option under Section 115BAA of the Income Tax Act, 1961, which has been duly reflected in the tax expense. This strategic tax decision appears to have favourably impacted the bottom line, complementing the robust top-line growth. While QoQ data is not provided, the strong YoY trends suggest sustained demand and effective cost management.

Risks & Outlook:

No explicit forward-looking guidance or management commentary on future outlook was provided in this results release. However, the strong performance in Q3 FY26, particularly the significant PAT growth outpacing revenue growth on a YoY basis, suggests healthy margin expansion and operational efficiencies. Investors should monitor future commentary for insights into sustained growth drivers, market positioning, and any potential headwinds.

This strong financial display underscores Titan Biotech's operational strength and market traction, presenting a positive picture for shareholders. The limited review by statutory auditors adds a layer of assurance to these unaudited results.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.